DataMeds AI Faces Nasdaq Delisting Risk Following Heavy Second-Quarter Losses
New York, Monday, 17 August 2026.
Despite reporting $1.8 million in second-quarter revenue, DataMeds AI incurred an $18.4 million loss, leaving the company with a $19.5 million equity deficit ahead of an October Nasdaq compliance deadline.
Second-Quarter Financial Performance and Revenue Analysis
DataMeds AI, Inc. reported second-quarter 2026 revenue of $1.779 million, a figure management highlighted as a 14% increase in their August 17, 2026, press release [1]. However, SEC filings indicate net revenues for the quarter ended June 30, 2026, were $1,779,860, down from $7,790,865 in the same period of 2025 [2]. This change reflects a -77.155 shift in year-over-year revenue performance according to regulatory documents [2]. The company recorded a net operating loss of $18.363 million for the quarter, compared to a loss of $6.672 million in the second quarter of 2025 [2]. Management attributed the increased loss to debt extinguishment expenses and general administrative costs [2].
Nasdaq Compliance Status and Equity Deficit
As of June 30, 2026, DataMeds AI reported a stockholders’ deficit of $19.504 million, triggering compliance concerns with Nasdaq Listing Rule 5550(b)(1) [2]. The company received an extension until October 12, 2026, to evidence compliance with the minimum $2.5 million stockholders’ equity requirement [2]. Management noted substantial doubt about the ability to continue as a going concern given the financial position and liquidity constraints [2]. Total assets were reported at $32.759 million against total liabilities of $52.264 million as of the end of the second quarter [2].
Corporate Restructuring and Strategic Initiatives
In July 2026, the company officially changed its name from Wellgistics Health, Inc. to DataMeds AI, Inc., alongside a ticker symbol update to MEDS on the NASDAQ Capital Market [1]. This followed a 1:50 reverse stock split executed in May 2026 to mitigate delisting risks [1]. To support turnaround initiatives, the company secured $6.5 million in new funding in June 2026 [1]. Management plans to launch the Health Lives Here consumer app in September 2026, targeting rural patients using GLP-1 agonists [1]. Additionally, a Dream Bowl Meme Coin I token distribution is scheduled for September 9, 2026, for shareholders of record as of August 7, 2026 [1].